8-K: Metagenomi Reports Positive Business Updates and Full Year 2024 Financial Results, Showcasing Progress in Gene Editing Therapies

Metagenomi announces advancements in its hemophilia A program, progress in cardiometabolic indications through the Ionis collaboration, and a strong cash position to support operations into 2027.

Summary

• Metagenomi reported its full year 2024 financial results and provided business updates on March 17, 2025.
• The company is focused on developing curative genetic medicines using its AI-driven metagenomics platform.
• Significant progress was made in the hemophilia A program (MGX-001), including the declaration of a development candidate and positive data from non-human primate (NHP) studies showing sustained Factor VIII (FVIII) activity for over 16 months.
• Metagenomi is leveraging the MGX-001 platform to advance a wholly-owned program for an undisclosed secreted protein deficiency disorder.
• The company advanced four Wave 1 Ionis collaboration programs targeting cardiometabolic indications, achieving in vivo proof-of-concept in rodents across all four programs.
• Key technology achievements include the presentation of compact SMART nucleases and novel adenine base editors (ABEs) with high editing efficiency and specificity.
• Metagenomi anticipates filing IND/CTA submissions for MGX-001 in 2026 and demonstrating NHP proof-of-concept for a lead secreted protein deficiency target in 2025.
• The company expects to nominate one to two development candidates from the Ionis collaboration in 2025.
• Metagenomi's cash, cash equivalents, and available-for-sale marketable securities totaled $248.3 million as of December 31, 2024, providing a cash runway into 2027.
• Research and development (R&D) expenses were $109.2 million for the full year ended December 31, 2024, compared to $94.4 million for the full year ended December 31, 2023.
• General and administrative (G&A) expenses were $32.0 million for the full year ended December 31, 2024, compared to $28.8 million for the full year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant progress in key programs, strong financial position, and clear milestones. The tone is optimistic and forward-looking.

Positives

• Sustained Factor VIII activity in non-human primate (NHP) study for more than 16 months in the Hemophilia A program.
• Achievement of in vivo proof-of-concept in multiple secreted protein deficiencies.
• Progress of four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025.
• Strong cash position of $248.3 million, providing a cash runway into 2027.
• Demonstrated 95% protein knockdown in spontaneous hypertensive rats.
• Publication in Nature Communications describing novel, compact CRISPR-associated transposases (CAST).

Negatives

• Research and development (R&D) expenses increased from $94.4 million in 2023 to $109.2 million in 2024.
• General and administrative (G&A) expenses increased from $28.8 million in 2023 to $32.0 million in 2024.
• Net loss increased from $(68.255) million in 2023 to $(78.058) million in 2024.

Risks

• The company's success depends on its ability to develop and advance its programs and product candidates.
• Metagenomi's ability to maintain and establish collaborations or strategic partnerships is crucial.
• Regulatory approvals and filings are subject to uncertainties.
• The company operates in a very competitive and rapidly changing environment.
• Metagenomi's success depends on its ability to attract, integrate and retain key personnel.

Future Outlook

Metagenomi anticipates several milestones in 2025 and 2026, including IND/CTA filings for MGX-001, NHP proof-of-concept for secreted protein deficiencies, and development candidate nominations from the Ionis collaboration, with a cash runway into 2027.

Management Comments

• Brian C. Thomas, PhD, CEO and founder of Metagenomi, stated that the company made significant progress toward its goal of developing curative genetic medicines for patients in 2024.

Industry Context

Metagenomi is operating in the competitive field of gene editing, alongside companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. The company's focus on AI-driven metagenomics and a diverse toolbox of editing technologies positions it to address a wide range of genetic diseases. The collaboration with Ionis Pharmaceuticals highlights the industry trend of partnerships to accelerate drug development.

Comparison to Industry Standards

• Metagenomi's approach to gene editing, leveraging AI and metagenomics, is comparable to other leading companies in the field such as CRISPR Therapeutics and Editas Medicine, who are also developing novel gene editing technologies.
• The 16-month sustained Factor VIII activity in NHPs is a promising result, potentially competitive with other gene therapy approaches for hemophilia A, such as those being developed by BioMarin and Sangamo Therapeutics.
• The company's cash runway into 2027 provides a strong financial foundation, similar to other well-funded gene editing companies, allowing for continued investment in research and development.

Management Changes

Stakeholder Impact

• Shareholders: Positive progress in pipeline and strong cash position are favorable.
• Employees: Continued investment in R&D and program advancement provides job security and growth opportunities.
• Patients: Advancing programs towards clinical trials offers hope for new treatments.
• Partners: Collaboration with Ionis and other partners is strengthened by positive results.

Next Steps

• Complete ongoing NHP durability study for Hemophilia A program.
• Conduct Pre-IND and ex-US regulatory meetings.
• File IND / CTA submissions for Hemophilia A program.
• Nominate 1-2 DCs from Cardiometabolic Programs.
• Disclose indications for remaining Wave 1 targets.
• Initiate IND enabling activities.
• Nominate DC for Secreted Protein Deficiencies.
• Disclose lead indication for secreted protein deficiency platform.
• Achieve NHP PoC for Secreted Protein Deficiencies.
• Continue to advance early-stage pipeline for multiple future IND filings.

Key Dates